Get the Stockscreener App
13.34
7.93%
0.98
After Hours:
13.34
Evommune Inc stock is traded at $13.34, with a volume of 1.92M.
It is up +7.93% in the last 24 hours and down -33.03% over the past month.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
See More
Previous Close:
$12.36
Open:
$12.48
24h Volume:
1.92M
Relative Volume:
2.94
Market Cap:
$480.49M
Revenue:
$10.00M
Net Income/Loss:
$-75.99M
P/E Ratio:
-5.5879
EPS:
-2.3873
Net Cash Flow:
$-80.36M
1W Performance:
+0.38%
1M Performance:
-33.03%
6M Performance:
-17.65%
1Y Performance:
+0.00%
1-Day Range:
$12.36
$13.84
1-Week Range:
$12.07
$13.90
52-Week Range:
$12.07
$33.20
Evommune Inc Stock (EVMN) Company Profile
Name
Evommune Inc
Sector
Industry
Phone
(650) 223-7745
Address
1891 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
13.34 | 445.19M | 10.00M | -75.99M | -80.36M | -2.3873 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Resumed | Oppenheimer | Outperform |
| Jan-22-26 | Initiated | Oppenheimer | Outperform |
| Jan-08-26 | Initiated | Raymond James | Strong Buy |
| Jan-06-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-25 | Initiated | Evercore ISI | Outperform |
| Dec-01-25 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Morgan Stanley | Overweight |
| Dec-01-25 | Initiated | William Blair | Outperform |
View All
Evommune Inc Stock (EVMN) Latest News
Evommune, Inc. (EVMN) Securities Fraud InvestigationLevi & Korsinsky - Morningstar
Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Top 3 Health Care Stocks That May Rocket Higher In July - Benzinga
EVMNEvommune Inc Options - Finviz
Evommune, Inc. (NYSE: EVMN) Stock Price, News & Analysis - Kalkine
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market - TipRanks
Evommune’s Healthy Balance Sheet Buys Them Time For AD (NYSE:EVMN) - Seeking Alpha
Evommune drops on phase 2 data for EVO756 in urticaria - MSN
Oral CSU Drug Falls Short in Phase 2b Study; Evommune Ends Development - The Dermatology Digest
Evommune shares plunge 38% after lead drug fails Phase 2b trial; insiders sold shares days before news. - Pluang
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) - PR Newswire
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal - The Globe and Mail
Evommune stock downgraded by H.C. Wainwright after trial failure - Investing.com South Africa
EVMN Maintained by Morgan Stanley -- Price Target Lowered to $26 - GuruFocus
Morgan Stanley Maintains Evommune(EVMN.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Evommune Inc : RBC Cuts Target Price to $30 F - Moomoo
A Quick Look at Today's Ratings for Evommune(EVMN.US), With a Forecast Between $26 to $28 - Moomoo
This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes - BioSpace
HC Wainwright Downgrades Evommune to Neutral From Buy - marketscreener.com
Evommune drops EVO756 in CSU after Phase IIb failure - The Pharma Letter
Evommune terminates oral drug’s development in CSU - Clinical Trials Arena
Evommune (EVO) Faces Setback as EVO756 Fails Key Trial for Chron - GuruFocus
Sectoral Asset Management Inc's Evommune Inc(EVMN) Holding History - GuruFocus
Evommune shares slide after phase 2b CSU trial misses main goal (EVMN) - MSN
Evommune, Inc. Stock 12‑Month Price Target Cut to $39.33, Implies 56% Upside - TradingView
EVMN Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
Evommune Still Has Shot At Atopic Dermatitis With EVO756 After Urticaria Failure - insights.citeline.com
Evommune stock rating cut to Market Perform by William Blair - Investing.com UK
Less than a year after IPO, Evommune stock is getting pummeled — here's why - The Business Journals
Evommune, Inc.(NYSE: EVMN) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Evommune, Inc.(NYSE: EVMN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Evommune, Inc.(NYSE: EVMN) dropped from Russell 3000E Value Benchmark - marketscreener.com
Why is Evommune stock plummeting today? By Investing.com - Investing.com India
Evommune, Inc.(NYSE: EVMN) dropped from Russell 2500 Value Benchmark - marketscreener.com
Evommune, Inc.(NYSE: EVMN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Evommune's EVO756 Misses Primary End Point in Phase 2b CSU Trial, Development Continues in AD and Migraine - Dermatology Times
Why is Evommune stock plummeting today? - Investing.com UK
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Evommune's Skin Disorder Study Falls Short - Benzinga
Evommune slips as oral drug fails mid-stage urticaria study - FirstWord Pharma
Evommune’s EVO756 Fails Phase 2b in Chronic Spontaneous Urticaria but Advances in Atopic Dermatitis and Migraine Trials – Minichart - Minichart
Evommune (EVMN) Reports Phase 2b Trial Results for EVO756 - GuruFocus
Raymond James cuts Evommune stock rating on trial miss By Investing.com - Investing.com Nigeria
Raymond James cuts Evommune stock rating on trial miss - Investing.com
Evommune Inc Stock (EVMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):